Is This Drugmaker Making the Right Moves, in the Right Places?

AstraZeneca (NYSE: AZN  ) is commonly recognized as one of the most fragile Big Pharma stocks on the market. While its peers, such as GlaxoSmithKline (NYSE: GSK  ) and Pfizer (NYSE: PFE  ) , have restructured their R&D strategies or spun out divisions, AstraZeneca has only recently started to make changes. Last autumn, the company suspended its share-buyback program in an effort to preserve cash, reshuffled its management team, and today announced its boldest move yet: It's moving its headquarters and shifting focus to three primary R&D sites. In the following video, Motley Fool analyst Max Macaluso discusses why investors should take notice of the company's bold plans.

What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.